Login to Your Account

Immunomedics Partners Lupus Drug, Epratuzumab, With UCB

By Karen Pihl-Carey

Thursday, May 11, 2006
It was almost a year ago that Immunomedics Inc. began two pivotal Phase III studies of epratuzumab to treat systemic lupus erythematosus. It said Wednesday it had licensed exclusive worldwide rights to develop, market and sell the product for all autoimmune disease indications to UCB SA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription